New Study, Medication Gives Hope to CRPS-RSD Victims – Legal Examiner
Axsome Therapeutics, Inc., a biopharmaceutical company dedicated to developing therapies for the treatment of pain and other central nervous system disorders, announced last month that the first patient has been enrolled in the CREATE-1 (CRPS Treatment Evaluation 1) study, a Phase 3 trial evaluating the effectiveness and safety of disodium zoledronate (AXS-02) in the treatment of the pain associated with complex regional pain syndrome (CRPS), also known as reflex sympathetic dystrophy (RSD).
The CREATE-1 study is expected to enroll 190 patients at sites in the U.S., Canada, Europe, and Australia. Eligible patients will be treated with either AXS-02 or a placebo, and the primary objective will be to measure the change in patient-reported pain intensity, measured with the Numerical Rating Scale.
FDA Fast Tracks AXS-02
In March 2015, the U.S. Food and Drug Administration (FDA) granted “Fast Track” designation to AXS-02 for the treatment of the pain associated with CRPS/RSD. AXS-02 is an osteoclast inhibitor being developed as an oral, non-opiod medication to treat the chronic pain. It is an investigational medication not yet approved by the FDA, and its safety and efficacy have not yet been determined. Read more here…
Posted by Bryan Pope
September 29, 2015 10:42 AM
Source: CRPS In the News
(Copied as online data is not static and this should be retained, please know, all right are to the author and her original publication)